Recent advances in the management of AL Amyloidosis

Summary Immunoglobulin light chain (AL) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive from the aggregation of misfolded monoclonal immunoglobulin light chains. Amyloid fibrils disrupt tissue architecture and the pre‐fibril...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology Vol. 172; no. 2; pp. 170 - 186
Main Authors: Kastritis, Efstathios, Dimopoulos, Meletios A.
Format: Journal Article
Language:English
Published: England 01.01.2016
Subjects:
Amyloidosis - diagnosis
Amyloidosis - immunology
Amyloidosis - therapy
heart failure
Humans
Immunoglobulin Light Chains - metabolism
Immunoglobulin Light-chain Amyloidosis
immunoglobulins
light chains
mass spectrometry
Melphalan - therapeutic use
monoclonal antibodies
Myeloablative Agonists - therapeutic use
Plasma Cells - drug effects
Plasma Cells - pathology
Risk Assessment - methods
Stem Cell Transplantation - methods
Treatment Outcome
heart failure
mass spectrometry
light chains
immunoglobulins
monoclonal antibodies
ISSN:0007-1048, 1365-2141, 1365-2141
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Summary Immunoglobulin light chain (AL) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive from the aggregation of misfolded monoclonal immunoglobulin light chains. Amyloid fibrils disrupt tissue architecture and the pre‐fibril oligomers are directly toxic to myocardiac cells, causing cardiac dysfunction. The lethal consequences of AL amyloidosis are due to the toxic product and not due to the malignant behaviour of the plasma cell clone; however, the characteristics of this clone are associated with long‐term prognosis. Early and accurate diagnosis is the key to effective management, but is challenging. Modern chemotherapy options (including autologous transplantation, bortezomib, lenalidomide) have improved the outcomes of patients at low or intermediate risk, but the prognosis of patients with severe cardiac dysfunction is still poor. Therapies targeting amyloid deposits and the amyloidogenic process are under investigation and offer promise for better future treatments.
AbstractList Summary Immunoglobulin light chain (AL) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive from the aggregation of misfolded monoclonal immunoglobulin light chains. Amyloid fibrils disrupt tissue architecture and the pre‐fibril oligomers are directly toxic to myocardiac cells, causing cardiac dysfunction. The lethal consequences of AL amyloidosis are due to the toxic product and not due to the malignant behaviour of the plasma cell clone; however, the characteristics of this clone are associated with long‐term prognosis. Early and accurate diagnosis is the key to effective management, but is challenging. Modern chemotherapy options (including autologous transplantation, bortezomib, lenalidomide) have improved the outcomes of patients at low or intermediate risk, but the prognosis of patients with severe cardiac dysfunction is still poor. Therapies targeting amyloid deposits and the amyloidogenic process are under investigation and offer promise for better future treatments.
Immunoglobulin light chain ( AL ) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive from the aggregation of misfolded monoclonal immunoglobulin light chains. Amyloid fibrils disrupt tissue architecture and the pre‐fibril oligomers are directly toxic to myocardiac cells, causing cardiac dysfunction. The lethal consequences of AL amyloidosis are due to the toxic product and not due to the malignant behaviour of the plasma cell clone; however, the characteristics of this clone are associated with long‐term prognosis. Early and accurate diagnosis is the key to effective management, but is challenging. Modern chemotherapy options (including autologous transplantation, bortezomib, lenalidomide) have improved the outcomes of patients at low or intermediate risk, but the prognosis of patients with severe cardiac dysfunction is still poor. Therapies targeting amyloid deposits and the amyloidogenic process are under investigation and offer promise for better future treatments.
Immunoglobulin light chain (AL) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive from the aggregation of misfolded monoclonal immunoglobulin light chains. Amyloid fibrils disrupt tissue architecture and the pre-fibril oligomers are directly toxic to myocardiac cells, causing cardiac dysfunction. The lethal consequences of AL amyloidosis are due to the toxic product and not due to the malignant behaviour of the plasma cell clone; however, the characteristics of this clone are associated with long-term prognosis. Early and accurate diagnosis is the key to effective management, but is challenging. Modern chemotherapy options (including autologous transplantation, bortezomib, lenalidomide) have improved the outcomes of patients at low or intermediate risk, but the prognosis of patients with severe cardiac dysfunction is still poor. Therapies targeting amyloid deposits and the amyloidogenic process are under investigation and offer promise for better future treatments.
Immunoglobulin light chain (AL) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive from the aggregation of misfolded monoclonal immunoglobulin light chains. Amyloid fibrils disrupt tissue architecture and the pre-fibril oligomers are directly toxic to myocardiac cells, causing cardiac dysfunction. The lethal consequences of AL amyloidosis are due to the toxic product and not due to the malignant behaviour of the plasma cell clone; however, the characteristics of this clone are associated with long-term prognosis. Early and accurate diagnosis is the key to effective management, but is challenging. Modern chemotherapy options (including autologous transplantation, bortezomib, lenalidomide) have improved the outcomes of patients at low or intermediate risk, but the prognosis of patients with severe cardiac dysfunction is still poor. Therapies targeting amyloid deposits and the amyloidogenic process are under investigation and offer promise for better future treatments.Immunoglobulin light chain (AL) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive from the aggregation of misfolded monoclonal immunoglobulin light chains. Amyloid fibrils disrupt tissue architecture and the pre-fibril oligomers are directly toxic to myocardiac cells, causing cardiac dysfunction. The lethal consequences of AL amyloidosis are due to the toxic product and not due to the malignant behaviour of the plasma cell clone; however, the characteristics of this clone are associated with long-term prognosis. Early and accurate diagnosis is the key to effective management, but is challenging. Modern chemotherapy options (including autologous transplantation, bortezomib, lenalidomide) have improved the outcomes of patients at low or intermediate risk, but the prognosis of patients with severe cardiac dysfunction is still poor. Therapies targeting amyloid deposits and the amyloidogenic process are under investigation and offer promise for better future treatments.
Author Dimopoulos, Meletios A.
Kastritis, Efstathios
Author_xml – sequence: 1
  givenname: Efstathios
  surname: Kastritis
  fullname: Kastritis, Efstathios
  organization: School of Medicine
– sequence: 2
  givenname: Meletios A.
  surname: Dimopoulos
  fullname: Dimopoulos, Meletios A.
  organization: School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26491974$$D View this record in MEDLINE/PubMed
BookMark eNp1kEtPwzAQhC1URB9w4A-gHOGQ1nZsxzmWCiioEhKCs-UndZU4JU5B_fektL0g2Msc9pvR7gxBL9TBAnCJ4Bh1M1Gr5RhlHNITMEAZoylGBPXAAEKYpwgS3gfDGFcQogxSdAb6mJECFTkZgOzFahvaRJpPGbSNiQ9Ju7RJJYN8t9VuVbtkukim1basvamjj-fg1Mky2ouDjsDb_d3rbJ4unh8eZ9NFqgnujtDUysJwarWSVuEcEcdIpginRjFZOCOdwhhT3ikxnLvCOMNUwaRGWGKajcD1Pnfd1B8bG1tR-ahtWcpg600UKGeQs4wQ0qFXB3SjKmvEuvGVbLbi-GgHTPaAbuoYG-uE9q1sfR3aRvpSICh2VYquSvFTZee4-eU4hv7FHtK_fGm3_4Pi9mm-d3wDunyBkA
CitedBy_id crossref_primary_10_1016_j_ccl_2019_07_013
crossref_primary_10_1016_j_clml_2016_01_003
crossref_primary_10_1016_j_cpcardiol_2023_101912
crossref_primary_10_1186_s13023_022_02584_3
crossref_primary_10_1146_annurev_biochem_061516_045115
crossref_primary_10_3390_jcm13154330
crossref_primary_10_3390_cardiogenetics11010002
crossref_primary_10_1016_j_ejim_2018_05_004
crossref_primary_10_1038_leu_2016_369
crossref_primary_10_1016_j_jaccao_2022_08_009
crossref_primary_10_1080_14728222_2017_1398235
crossref_primary_10_1016_j_jjcc_2023_02_009
crossref_primary_10_1097_HS9_0000000000000687
crossref_primary_10_1016_j_clml_2024_05_004
crossref_primary_10_1038_s41598_019_39781_3
crossref_primary_10_3390_diseases9020040
crossref_primary_10_1002_hon_2351
crossref_primary_10_1016_j_ijbiomac_2022_05_127
crossref_primary_10_1002_ehf2_12793
crossref_primary_10_1182_bloodadvances_2019000147
crossref_primary_10_1159_000508262
crossref_primary_10_1016_j_cjca_2019_12_033
crossref_primary_10_3389_fmed_2024_1477988
crossref_primary_10_1097_MD_0000000000005645
crossref_primary_10_1007_s12105_017_0831_0
crossref_primary_10_1038_s41467_021_26845_0
crossref_primary_10_3389_fcvm_2021_751293
crossref_primary_10_1016_j_ijcard_2018_05_018
crossref_primary_10_1016_j_mayocp_2016_06_027
crossref_primary_10_1007_s13730_020_00539_w
crossref_primary_10_1093_ndt_gfw305
crossref_primary_10_12998_wjcc_v10_i28_10252
crossref_primary_10_1007_s00277_018_3460_0
crossref_primary_10_1016_j_carpath_2019_107191
crossref_primary_10_1016_j_labcli_2017_04_001
crossref_primary_10_7554_eLife_52300
crossref_primary_10_4251_wjgo_v16_i2_550
crossref_primary_10_4178_epih_e2024078
crossref_primary_10_1007_s12185_020_02835_8
crossref_primary_10_1097_ICB_0000000000001061
crossref_primary_10_1182_blood_2017_02_767475
crossref_primary_10_3390_ijms222010916
crossref_primary_10_1007_s00380_019_01513_y
crossref_primary_10_1136_bcr_2019_232934
crossref_primary_10_1007_s12016_019_08759_4
crossref_primary_10_1016_j_cca_2019_03_1624
crossref_primary_10_1002_cncr_30051
crossref_primary_10_1080_17474086_2021_2003704
crossref_primary_10_1097_01_JAA_0000753944_15711_96
crossref_primary_10_1016_j_critrevonc_2021_103435
crossref_primary_10_1002_hon_2417
crossref_primary_10_1038_s41375_021_01317_y
crossref_primary_10_1111_bjh_14585
crossref_primary_10_1007_s10741_020_10062_w
crossref_primary_10_1016_j_jacc_2016_06_053
crossref_primary_10_1111_bjh_14587
crossref_primary_10_1159_000507612
crossref_primary_10_1371_journal_pone_0235143
crossref_primary_10_1159_000447304
crossref_primary_10_1007_s11886_019_1230_9
crossref_primary_10_1016_j_bbmt_2017_05_020
crossref_primary_10_1016_j_leukres_2017_06_008
crossref_primary_10_1038_s41408_018_0086_3
crossref_primary_10_1080_13506129_2018_1540410
crossref_primary_10_31146_1682_8658_ecg_213_5_156_159
crossref_primary_10_1038_srep42880
Cites_doi 10.1182/blood-2006-07-035352
10.1177/0004563212473447
10.1038/nature09494
10.1182/blood.V124.21.4741.4741
10.1182/blood-2014-06-580720
10.1182/blood-2014-04-570010
10.4065/83.11.1226
10.1182/blood-2008-02-138156
10.3109/13506129.2013.854766
10.1038/bmt.2013.53
10.1111/j.1365-2141.2009.08036.x
10.1093/eurheartj/ehu506
10.1200/JCO.2014.57.4947
10.1182/blood-2015-01-620302
10.1182/blood-2012-01-407791
10.3109/10428194.2010.524329
10.1002/art.22959
10.1038/bmt.2014.115
10.3324/haematol.2013.095463
10.1161/01.RES.0000126569.75419.74
10.1007/s00392-010-0142-x
10.1212/WNL.0b013e3181d55f4d
10.3109/13506129.2011.574354029
10.1016/j.healun.2013.09.004
10.1182/blood-2011-07-365510
10.1371/journal.pone.0052686
10.1182/blood-2004-08-3231
10.1200/JCO.2010.30.5235
10.1002/ajh.23827
10.1093/qjmed/hcr105
10.1038/bmt.2012.170
10.1586/17474086.2014.858594
10.1182/blood-2006-07-030544
10.1053/j.ajkd.2008.05.022
10.3324/haematol.11325
10.1200/JCO.2011.38.5724
10.1200/JCO.2011.37.7614
10.1182/blood-2011-01-330738
10.1001/archinte.1988.00380040169024
10.1182/blood-2012-12-473066
10.1182/blood.V124.21.35.35
10.1182/blood-2003-08-2788
10.1182/blood-2011-12-396903
10.3324/haematol.13369
10.1182/blood-2011-10-388462
10.3324/haematol.12982
10.1056/NEJMoa1404852
10.1038/leu.2012.274
10.1182/blood.V74.3.1108.1108
10.3324/haematol.2014.104109
10.1002/ajh.20381
10.15252/emmm.201404190
10.1111/j.1600-6143.2010.03227.x
10.1002/ajh.23936
10.1038/ki.2014.122
10.1111/bjh.13155
10.3324/haematol.2013.084574
10.1182/blood.V124.21.3450.3450
10.1182/blood.V124.21.3485.3485
10.1182/blood-2009-07-230722
10.1111/jce.12123
10.1182/blood-2014-11-609883
10.1046/j.1460-9592.2001.01228.x
10.1016/j.healun.2013.01.987
10.1016/j.hoc.2014.08.013
10.1056/NEJMoa065644
10.1200/JCO.2013.50.8499
10.1182/blood-2011-11-390930
10.3109/13506129.2010.543443
10.1056/NEJM199008233230803
10.1182/blood-2011-02-334227
10.1182/blood-2013-10-525634
10.1152/ajpheart.00186.2013
10.1182/blood-2011-05-355784
10.1002/ajh.21822
10.1016/0002-9343(88)90505-0
10.1073/pnas.0912263107
10.1182/blood-2012-02-413161
10.1200/JCO.2004.03.029
10.1056/NEJMoa070484
10.1056/NEJMoa1504942
10.1161/01.CIR.63.6.1285
10.1182/blood-2010-02-268987
10.1111/bjh.13500
10.1111/j.1365-2141.2010.08288.x
10.1161/circ.104.14.1594
10.1097/TP.0b013e3181f10edb
10.1016/j.jcmg.2011.03.016
10.1038/leu.2014.218
10.1038/leu.2014.227
10.2353/ajpath.2006.060183
10.1182/blood-2011-04-351643
10.1182/blood-2006-07-032987
10.1200/JCO.2009.23.8220
10.1093/ndt/gfs492
10.1182/blood-2011-06-358507
10.1038/sj.bmt.1704691
10.1182/blood-2010-07-294405
10.1056/NEJMra023144
10.1038/bcj.2015.45
10.1182/blood-2004-04-1424
10.1182/blood.V122.21.288.288
ContentType Journal Article
Copyright 2015 John Wiley & Sons Ltd
2015 John Wiley & Sons Ltd.
Copyright_xml – notice: 2015 John Wiley & Sons Ltd
– notice: 2015 John Wiley & Sons Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/bjh.13805
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2141
EndPage 186
ExternalDocumentID 26491974
10_1111_bjh_13805
BJH13805
Genre reviewArticle
Journal Article
Review
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1KJ
1OB
1OC
23N
24P
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6J9
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8F7
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAYEP
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHEFC
AI.
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EGARE
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IH2
IHE
IX1
J0M
J5H
K48
KBYEO
L7B
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
UB1
V8K
V9Y
VH1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAMMB
AAYXX
AEFGJ
AEYWJ
AGHNM
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
AIQQE
CITATION
O8X
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c4265-c5ea9d85ecbaeb2714f643b485db6a9fdafb22258afb4d88f9dfd6b96ac12a253
IEDL.DBID WIN
ISICitedReferencesCount 72
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000367900200004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0007-1048
1365-2141
IngestDate Sun Nov 09 12:57:15 EST 2025
Mon Jul 21 06:04:31 EDT 2025
Tue Nov 18 22:34:18 EST 2025
Sat Nov 29 03:24:26 EST 2025
Wed Jan 22 17:11:04 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords heart failure
mass spectrometry
light chains
immunoglobulins
monoclonal antibodies
Language English
License 2015 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4265-c5ea9d85ecbaeb2714f643b485db6a9fdafb22258afb4d88f9dfd6b96ac12a253
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.13805
PMID 26491974
PQID 1760863444
PQPubID 23479
PageCount 17
ParticipantIDs proquest_miscellaneous_1760863444
pubmed_primary_26491974
crossref_citationtrail_10_1111_bjh_13805
crossref_primary_10_1111_bjh_13805
wiley_primary_10_1111_bjh_13805_BJH13805
PublicationCentury 2000
PublicationDate January 2016
PublicationDateYYYYMMDD 2016-01-01
PublicationDate_xml – month: 01
  year: 2016
  text: January 2016
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle British journal of haematology
PublicationTitleAlternate Br J Haematol
PublicationYear 2016
References 2012b; 120
2004; 22
2010; 99
2010; 10
2015; 36
2011; 118
2013; 28
2011; 117
2013; 27
2010; 107
2010; 468
2013; 24
2010; 148
2015; 33
2013; 122
2013; 121
2014; 28
2007; 109
2011; 18
2001; 104
2014c; 28
2009; 114
2014; 21
1988; 148
2015; 372
1989; 74
2015; 170
2014b; 99
2013; 98
2009; 94
2015a; 5
2010; 116
2013; 50
2005; 105
2004; 34
2012a; 30
2015; 373
1988; 85
2008; 112
2014; 6
2011; 29
2010; 74
2014; 99
2014; 123
2005; 79
2006; 169
2014; 124
2014a; 7
2013; 48
2015b; 90
2010a; 150
1990; 323
2004; 103
2015; 126
2015; 168
2015; 125
2013; 305
2014; 49
2007; 92
2008; 52
2011; 4
2014b; 124
2001; 24
1981; 63
2008; 93
2007; 56
2010; 85
2014; 89
2014; 86
2007; 356
2010b; 28
2011; 104
2007; 357
2004; 94
2003; 349
2013; 32
2013; 31
2014a; 124
2012b; 119
2008; 83
2012; 7
2010; 90
2012; 119
2010; 51
2014; 33
e_1_2_15_104_1
e_1_2_15_42_1
e_1_2_15_88_1
e_1_2_15_69_1
Cohen A.D. (e_1_2_15_12_1) 2014; 124
e_1_2_15_3_1
e_1_2_15_80_1
e_1_2_15_61_1
e_1_2_15_84_1
e_1_2_15_23_1
e_1_2_15_65_1
e_1_2_15_7_1
e_1_2_15_31_1
e_1_2_15_77_1
Gertz M.A. (e_1_2_15_28_1) 1989; 74
e_1_2_15_58_1
e_1_2_15_100_1
e_1_2_15_16_1
e_1_2_15_50_1
e_1_2_15_92_1
e_1_2_15_35_1
e_1_2_15_73_1
e_1_2_15_54_1
e_1_2_15_96_1
e_1_2_15_20_1
e_1_2_15_43_1
e_1_2_15_66_1
e_1_2_15_89_1
e_1_2_15_81_1
e_1_2_15_2_1
e_1_2_15_24_1
e_1_2_15_47_1
e_1_2_15_85_1
e_1_2_15_6_1
e_1_2_15_32_1
e_1_2_15_55_1
e_1_2_15_78_1
Gertz M.A. (e_1_2_15_34_1) 2015; 33
e_1_2_15_59_1
e_1_2_15_17_1
e_1_2_15_70_1
e_1_2_15_93_1
e_1_2_15_101_1
e_1_2_15_13_1
e_1_2_15_36_1
e_1_2_15_51_1
e_1_2_15_74_1
e_1_2_15_97_1
e_1_2_15_106_1
Kastritis E. (e_1_2_15_46_1) 2014; 124
e_1_2_15_21_1
e_1_2_15_67_1
e_1_2_15_40_1
Gertz M.A. (e_1_2_15_27_1) 1988; 148
Wechalekar A. (e_1_2_15_105_1) 2014; 124
e_1_2_15_29_1
e_1_2_15_48_1
e_1_2_15_82_1
e_1_2_15_25_1
e_1_2_15_63_1
e_1_2_15_44_1
e_1_2_15_86_1
e_1_2_15_9_1
e_1_2_15_90_1
e_1_2_15_5_1
Hegenbart U. (e_1_2_15_39_1) 2014; 99
e_1_2_15_10_1
e_1_2_15_56_1
e_1_2_15_79_1
e_1_2_15_18_1
e_1_2_15_94_1
e_1_2_15_102_1
e_1_2_15_37_1
e_1_2_15_71_1
e_1_2_15_14_1
e_1_2_15_52_1
Milani P. (e_1_2_15_64_1) 2013; 122
e_1_2_15_98_1
e_1_2_15_33_1
e_1_2_15_75_1
e_1_2_15_103_1
e_1_2_15_19_1
e_1_2_15_41_1
e_1_2_15_68_1
e_1_2_15_26_1
e_1_2_15_49_1
e_1_2_15_60_1
e_1_2_15_83_1
e_1_2_15_22_1
e_1_2_15_45_1
e_1_2_15_87_1
e_1_2_15_8_1
Merlini G. (e_1_2_15_62_1) 2014; 124
e_1_2_15_4_1
Palladini G. (e_1_2_15_72_1) 2012; 120
e_1_2_15_30_1
e_1_2_15_57_1
e_1_2_15_99_1
e_1_2_15_15_1
e_1_2_15_38_1
e_1_2_15_91_1
e_1_2_15_11_1
e_1_2_15_53_1
e_1_2_15_76_1
e_1_2_15_95_1
References_xml – volume: 119
  start-page: 5384
  year: 2012
  end-page: 5390
  article-title: A phase 1/2 study of lenalidomide with low‐dose oral cyclophosphamide and low‐dose dexamethasone (RdC) in AL amyloidosis
  publication-title: Blood
– volume: 119
  start-page: 4391
  year: 2012
  end-page: 4394
  article-title: Cyclophosphamide‐bortezomib‐dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
  publication-title: Blood
– volume: 468
  start-page: 93
  year: 2010
  end-page: 97
  article-title: Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
  publication-title: Nature
– volume: 124
  start-page: 35
  year: 2014
  end-page: 35
  article-title: A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis
  publication-title: Blood
– volume: 7
  start-page: e52686
  year: 2012
  article-title: AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils
  publication-title: PLoS ONE
– volume: 27
  start-page: 823
  year: 2013
  end-page: 828
  article-title: Bortezomib and dexamethasone consolidation following risk‐adapted melphalan and stem cell transplantation for patients with newly diagnosed light‐chain amyloidosis
  publication-title: Leukemia
– volume: 323
  start-page: 508
  year: 1990
  end-page: 513
  article-title: Evaluation of systemic amyloidosis by scintigraphy with 123I‐labeled serum amyloid P component
  publication-title: New England Journal of Medicine
– volume: 89
  start-page: 1051
  year: 2014
  end-page: 1054
  article-title: Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias
  publication-title: American Journal of Hematology
– volume: 49
  start-page: 1036
  year: 2014
  end-page: 1041
  article-title: Auto‐SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14‐year follow‐up
  publication-title: Bone Marrow Transplantation
– volume: 28
  start-page: 1131
  year: 2014
  end-page: 1144
  article-title: High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis
  publication-title: Hematology/oncology Clinics of North America
– volume: 74
  start-page: 1108
  year: 1989
  end-page: 1111
  article-title: The plasma cell labeling index: a valuable tool in primary systemic amyloidosis
  publication-title: Blood
– volume: 30
  start-page: 4541
  year: 2012a
  end-page: 4549
  article-title: New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes
  publication-title: Journal of Clinical Oncology
– volume: 85
  start-page: 757
  year: 2010
  end-page: 759
  article-title: Discordance between serum cardiac biomarker and immunoglobulin‐free light‐chain response in patients with immunoglobulin light‐chain amyloidosis treated with immune modulatory drugs
  publication-title: American Journal of Hematology
– volume: 305
  start-page: H95
  year: 2013
  end-page: H103
  article-title: Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish
  publication-title: American Journal of Physiology ‐ Heart and Circulatory Physiology
– volume: 104
  start-page: 1594
  year: 2001
  end-page: 1597
  article-title: Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts
  publication-title: Circulation
– volume: 168
  start-page: 186
  year: 2015
  end-page: 206
  article-title: Guidelines on the management of AL amyloidosis
  publication-title: British Journal of Haematology
– volume: 94
  start-page: 380
  year: 2009
  end-page: 386
  article-title: Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis
  publication-title: Haematologica
– volume: 6
  start-page: 1493
  year: 2014
  end-page: 1507
  article-title: Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain‐mediated cardiotoxicity
  publication-title: EMBO Molecular Medicine
– volume: 103
  start-page: 2936
  year: 2004
  end-page: 2938
  article-title: Association of melphalan and high‐dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
  publication-title: Blood
– volume: 109
  start-page: 465
  year: 2007
  end-page: 470
  article-title: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
  publication-title: Blood
– volume: 372
  start-page: 21
  year: 2015
  end-page: 29
  article-title: The amyloidogenic V122I transthyretin variant in elderly black Americans
  publication-title: New England Journal of Medicine
– volume: 124
  start-page: 2325
  year: 2014a
  end-page: 2332
  article-title: A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
  publication-title: Blood
– volume: 28
  start-page: 2311
  year: 2014c
  end-page: 2316
  article-title: Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case‐control study on 174 patients
  publication-title: Leukemia
– volume: 169
  start-page: 1939
  year: 2006
  end-page: 1952
  article-title: Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts
  publication-title: American Journal of Pathology
– volume: 105
  start-page: 794
  year: 2005
  end-page: 803
  article-title: Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis
  publication-title: Blood
– volume: 98
  start-page: 1593
  year: 2013
  end-page: 1599
  article-title: Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
  publication-title: Haematologica
– volume: 28
  start-page: 2304
  year: 2014
  end-page: 2310
  article-title: A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk‐adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis
  publication-title: Leukemia
– volume: 48
  start-page: 557
  year: 2013
  end-page: 561
  article-title: Refinement in patient selection to reduce treatment‐related mortality from autologous stem cell transplantation in amyloidosis
  publication-title: Bone Marrow Transplantation
– volume: 119
  start-page: 4387
  year: 2012
  end-page: 4390
  article-title: Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression‐free survival
  publication-title: Blood
– volume: 52
  start-page: 1079
  year: 2008
  end-page: 1083
  article-title: Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single‐center experience in 101 patients
  publication-title: American Journal of Kidney Diseases
– volume: 33
  start-page: 149
  year: 2014
  end-page: 156
  article-title: Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis
  publication-title: The Journal of Heart and Lung Transplantation
– volume: 99
  start-page: 1479
  year: 2014
  end-page: 1485
  article-title: Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment‐naive patients with high‐risk cardiac AL amyloidosis (Mayo Clinic stage III)
  publication-title: Haematologica
– volume: 50
  start-page: 255
  year: 2013
  end-page: 261
  article-title: A multicentre study comparing two methods for serum free light chain analysis
  publication-title: Annals of Clinical Biochemistry
– volume: 124
  start-page: 3450
  year: 2014b
  end-page: 3450
  article-title: Long‐Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light‐Chain (AL) Amyloidosis (RRAL)
  publication-title: Blood
– volume: 124
  start-page: 4741
  year: 2014
  article-title: A phase I dose‐escalation study of carfilzomib in patients with previously‐treated systemic light‐chain (AL) Amyloidosis
  publication-title: Blood
– volume: 116
  start-page: 4777
  year: 2010
  end-page: 4782
  article-title: Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose‐escalation study
  publication-title: Blood
– volume: 170
  start-page: 804
  year: 2015
  end-page: 813
  article-title: A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
  publication-title: British Journal of Haematology
– volume: 4
  start-page: 659
  year: 2011
  end-page: 670
  article-title: Role of (99 m)Tc‐DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin‐related cardiac amyloidosis
  publication-title: Journal of the American College of Cardiology ‐ Cardiovascular Imaging
– volume: 357
  start-page: 1083
  year: 2007
  end-page: 1093
  article-title: High‐dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
  publication-title: New England Journal of Medicine
– volume: 119
  start-page: 4860
  year: 2012b
  end-page: 4867
  article-title: Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light‐chain amyloidosis: long‐term results from a phase 2 trial
  publication-title: Blood
– volume: 119
  start-page: 1844
  year: 2012
  end-page: 1847
  article-title: Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue
  publication-title: Blood
– volume: 34
  start-page: 1025
  year: 2004
  end-page: 1031
  article-title: Risk‐adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate
  publication-title: Bone Marrow Transplantation
– volume: 79
  start-page: 319
  year: 2005
  end-page: 328
  article-title: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18‐22 April 2004
  publication-title: American Journal of Hematology
– volume: 118
  start-page: 865
  year: 2011
  end-page: 873
  article-title: Efficacy and safety of once‐weekly and twice‐weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
  publication-title: Blood
– volume: 63
  start-page: 1285
  year: 1981
  end-page: 1288
  article-title: Digoxin sensitivity in amyloid cardiomyopathy
  publication-title: Circulation
– volume: 36
  start-page: 1098
  year: 2015
  end-page: 1105
  article-title: A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis
  publication-title: European Heart Journal
– volume: 7
  start-page: 143
  year: 2014a
  end-page: 156
  article-title: Immunoglobulin light chain amyloidosis
  publication-title: Expert Review of Hematology
– volume: 18
  start-page: 80
  year: 2011
  end-page: 82
  article-title: The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients
  publication-title: Amyloid
– volume: 119
  start-page: 5397
  year: 2012
  end-page: 5404
  article-title: Activity of pomalidomide in patients with immunoglobulin light‐chain amyloidosis
  publication-title: Blood
– volume: 74
  start-page: 913
  year: 2010
  end-page: 918
  article-title: Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis
  publication-title: Neurology
– volume: 24
  start-page: 1228
  year: 2001
  end-page: 1233
  article-title: Holter monitoring in AL amyloidosis: prognostic implications
  publication-title: Pacing and Clinical Electrophysiology
– volume: 148
  start-page: 760
  year: 2010
  end-page: 767
  article-title: Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis
  publication-title: British Journal of Haematology
– volume: 118
  start-page: 6610
  year: 2011
  end-page: 6617
  article-title: Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis
  publication-title: Blood
– volume: 5
  start-page: e319
  year: 2015a
  article-title: Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging
  publication-title: Blood Cancer Journal
– volume: 119
  start-page: 488
  year: 2012
  end-page: 493
  article-title: Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients
  publication-title: Blood
– volume: 83
  start-page: 1226
  year: 2008
  end-page: 1230
  article-title: Patterns of neuropathy and autonomic failure in patients with amyloidosis
  publication-title: Mayo Clinic Proceedings
– volume: 99
  start-page: 483
  year: 2010
  end-page: 490
  article-title: Effects of the main green tea polyphenol epigallocatechin‐3‐gallate on cardiac involvement in patients with AL amyloidosis
  publication-title: Clinical Research in Cardiology
– volume: 122
  start-page: 288
  year: 2013
  end-page: 288
  article-title: High‐dose pomalidomide and dexamethasone induce rapid responses in patients with AL amyloidosis exposed to alkylators, immune modulatory drugs, and proteasome inhibitors
  publication-title: Blood
– volume: 86
  start-page: 738
  year: 2014
  end-page: 746
  article-title: An animal model of glomerular light‐chain‐associated amyloidogenesis depicts the crucial role of lysosomes
  publication-title: Kidney International
– volume: 56
  start-page: 3858
  year: 2007
  end-page: 3868
  article-title: Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival
  publication-title: Arthritis & Rheumatology
– volume: 124
  start-page: 3485
  year: 2014
  end-page: 3485
  article-title: A matched case control study of doxycycline added to chemotherapy for reducing early mortality in patients with advanced cardiac AL amyloidosis from the alchemy study cohort
  publication-title: Blood
– volume: 85
  start-page: 73
  year: 1988
  end-page: 80
  article-title: Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients
  publication-title: The American Journal of Medicine
– volume: 119
  start-page: 144
  year: 2012
  end-page: 150
  article-title: The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1‐44
  publication-title: Blood
– volume: 30
  start-page: 989
  year: 2012a
  end-page: 995
  article-title: Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
  publication-title: Journal of Clinical Oncology
– volume: 21
  start-page: 9
  year: 2014
  end-page: 17
  article-title: Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone
  publication-title: Amyloid
– volume: 24
  start-page: 793
  year: 2013
  end-page: 798
  article-title: Implantable cardioverter defibrillators in patients with cardiac amyloidosis
  publication-title: Journal of Cardiovascular Electrophysiology
– volume: 28
  start-page: 1031
  year: 2010b
  end-page: 1037
  article-title: Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis
  publication-title: Journal of Clinical Oncology
– volume: 118
  start-page: 4346
  year: 2011
  end-page: 4352
  article-title: Outcome of AL amyloidosis after high‐dose melphalan and autologous stem cell transplantation: long‐term results in a series of 421 patients
  publication-title: Blood
– volume: 10
  start-page: 2124
  year: 2010
  end-page: 2131
  article-title: Solid organ transplantation in AL amyloidosis
  publication-title: American Journal of Transplantation
– volume: 107
  start-page: 4188
  year: 2010
  end-page: 4193
  article-title: Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non‐canonical p38alpha MAPK pathway
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 32
  start-page: 563
  year: 2013
  end-page: 568
  article-title: Left ventricular device implantation for advanced cardiac amyloidosis
  publication-title: The Journal of Heart and Lung Transplantation
– volume: 349
  start-page: 583
  year: 2003
  end-page: 596
  article-title: Molecular mechanisms of amyloidosis
  publication-title: New England Journal of Medicine
– volume: 117
  start-page: 3809
  year: 2011
  end-page: 3815
  article-title: Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)
  publication-title: Blood
– volume: 124
  start-page: 3025
  year: 2014
  end-page: 3027
  article-title: Two types of amyloid in a single heart
  publication-title: Blood
– volume: 373
  start-page: 1106
  year: 2015
  end-page: 1114
  article-title: Therapeutic clearance of amyloid by antibodies to serum amyloid P component
  publication-title: New England Journal of Medicine
– volume: 109
  start-page: 492
  year: 2007
  end-page: 496
  article-title: Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
  publication-title: Blood
– volume: 114
  start-page: 4957
  year: 2009
  end-page: 4959
  article-title: Classification of amyloidosis by laser microdissection and mass spectrometry‐based proteomic analysis in clinical biopsy specimens
  publication-title: Blood
– volume: 99
  start-page: S1305
  year: 2014
  article-title: Long‐term results of 174 patients with systemic AL amyloidosis treated with high‐dose melphalan and autologous stem cell transplantation: a single center experience
  publication-title: Haematologica
– volume: 33
  start-page: 8514
  year: 2015
  article-title: Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction
  publication-title: Journal of Clinical Oncology (ASCO Meeting Abstracts)
– volume: 94
  start-page: 1008
  year: 2004
  end-page: 1010
  article-title: Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress
  publication-title: Circulation Research
– volume: 99
  start-page: 743
  year: 2014b
  end-page: 750
  article-title: Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long‐term results of a risk‐adapted approach
  publication-title: Haematologica
– volume: 51
  start-page: 2181
  year: 2010
  end-page: 2187
  article-title: Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report
  publication-title: Leukemia & Lymphoma
– volume: 18
  start-page: 19
  year: 2011
  end-page: 24
  article-title: Non‐invasive detection of hepatic amyloidosis: FibroScan, a new tool
  publication-title: Amyloid
– volume: 33
  start-page: 1371
  year: 2015
  end-page: 1378
  article-title: Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib‐based regimens
  publication-title: Journal of Clinical Oncology
– volume: 123
  start-page: 3543
  year: 2014
  end-page: 3552
  article-title: A Caenorhabditis elegans‐based assay recognizes immunoglobulin light chains causing heart amyloidosis
  publication-title: Blood
– volume: 109
  start-page: 457
  year: 2007
  end-page: 464
  article-title: Safety and efficacy of risk‐adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
  publication-title: Blood
– volume: 126
  start-page: 612
  year: 2015
  end-page: 615
  article-title: A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
  publication-title: Blood
– volume: 150
  start-page: 587
  year: 2010a
  end-page: 591
  article-title: High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients
  publication-title: British Journal of Haematology
– volume: 28
  start-page: 455
  year: 2013
  end-page: 461
  article-title: End‐stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases
  publication-title: Nephrology Dialysis Transplantation
– volume: 121
  start-page: 3420
  year: 2013
  end-page: 3427
  article-title: A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
  publication-title: Blood
– volume: 356
  start-page: 2349
  year: 2007
  end-page: 2360
  article-title: Eprodisate for the treatment of renal disease in AA amyloidosis
  publication-title: New England Journal of Medicine
– volume: 90
  start-page: 905
  year: 2010
  end-page: 911
  article-title: Cardiac transplantation followed by dose‐intensive melphalan and autologous stem‐cell transplantation for light chain amyloidosis and heart failure
  publication-title: Transplantation
– volume: 93
  start-page: 1402
  year: 2008
  end-page: 1406
  article-title: Long‐term risk of myelodysplasia in melphalan‐treated patients with immunoglobulin light‐chain amyloidosis
  publication-title: Haematologica
– volume: 148
  start-page: 929
  year: 1988
  end-page: 933
  article-title: Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain)
  publication-title: Archives of Internal Medicine
– volume: 90
  start-page: E60
  year: 2015b
  end-page: E65
  article-title: Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies
  publication-title: American Journal of Hematology
– volume: 29
  start-page: 674
  year: 2011
  end-page: 681
  article-title: Outcome in renal Al amyloidosis after chemotherapy
  publication-title: Journal of Clinical Oncology
– volume: 125
  start-page: 2239
  year: 2015
  end-page: 2244
  article-title: A practical approach to the diagnosis of systemic amyloidoses
  publication-title: Blood
– volume: 22
  start-page: 3751
  year: 2004
  end-page: 3757
  article-title: Serum cardiac troponins and N‐terminal pro‐brain natriuretic peptide: a staging system for primary systemic amyloidosis
  publication-title: Journal of Clinical Oncology
– volume: 31
  start-page: 4319
  year: 2013
  end-page: 4324
  article-title: Coexistent multiple myeloma or increased bone marrow plasma cells define equally high‐risk populations in patients with immunoglobulin light chain amyloidosis
  publication-title: Journal of Clinical Oncology
– volume: 120
  start-page: 4057
  year: 2012b
  article-title: Treatment of AL amyloidosis with bendamustine
  publication-title: Blood (ASH Annual Meeting Abstracts)
– volume: 104
  start-page: 957
  year: 2011
  end-page: 970
  article-title: Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
  publication-title: QJM
– volume: 48
  start-page: 1302
  year: 2013
  end-page: 1307
  article-title: Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center
  publication-title: Bone Marrow Transplantation
– volume: 92
  start-page: 1351
  year: 2007
  end-page: 1358
  article-title: Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
  publication-title: Haematologica
– volume: 105
  start-page: 2949
  year: 2005
  end-page: 2951
  article-title: The combination of thalidomide and intermediate‐dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
  publication-title: Blood
– volume: 112
  start-page: 4009
  year: 2008
  end-page: 4016
  article-title: AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome
  publication-title: Blood
– ident: e_1_2_15_102_1
  doi: 10.1182/blood-2006-07-035352
– ident: e_1_2_15_56_1
  doi: 10.1177/0004563212473447
– ident: e_1_2_15_6_1
  doi: 10.1038/nature09494
– volume: 124
  start-page: 4741
  year: 2014
  ident: e_1_2_15_12_1
  article-title: A phase I dose‐escalation study of carfilzomib in patients with previously‐treated systemic light‐chain (AL) Amyloidosis
  publication-title: Blood
  doi: 10.1182/blood.V124.21.4741.4741
– ident: e_1_2_15_58_1
  doi: 10.1182/blood-2014-06-580720
– ident: e_1_2_15_73_1
  doi: 10.1182/blood-2014-04-570010
– ident: e_1_2_15_100_1
  doi: 10.4065/83.11.1226
– volume: 33
  start-page: 8514
  year: 2015
  ident: e_1_2_15_34_1
  article-title: Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction
  publication-title: Journal of Clinical Oncology (ASCO Meeting Abstracts)
– ident: e_1_2_15_103_1
  doi: 10.1182/blood-2008-02-138156
– ident: e_1_2_15_4_1
  doi: 10.3109/13506129.2013.854766
– volume: 99
  start-page: S1305
  year: 2014
  ident: e_1_2_15_39_1
  article-title: Long‐term results of 174 patients with systemic AL amyloidosis treated with high‐dose melphalan and autologous stem cell transplantation: a single center experience
  publication-title: Haematologica
– ident: e_1_2_15_22_1
  doi: 10.1038/bmt.2013.53
– ident: e_1_2_15_35_1
  doi: 10.1111/j.1365-2141.2009.08036.x
– ident: e_1_2_15_89_1
  doi: 10.1093/eurheartj/ehu506
– ident: e_1_2_15_5_1
  doi: 10.1200/JCO.2014.57.4947
– ident: e_1_2_15_76_1
  doi: 10.1182/blood-2015-01-620302
– ident: e_1_2_15_52_1
  doi: 10.1182/blood-2012-01-407791
– ident: e_1_2_15_32_1
  doi: 10.3109/10428194.2010.524329
– ident: e_1_2_15_80_1
  doi: 10.1002/art.22959
– ident: e_1_2_15_77_1
  doi: 10.1038/bmt.2014.115
– ident: e_1_2_15_74_1
  doi: 10.3324/haematol.2013.095463
– ident: e_1_2_15_8_1
  doi: 10.1161/01.RES.0000126569.75419.74
– ident: e_1_2_15_59_1
  doi: 10.1007/s00392-010-0142-x
– ident: e_1_2_15_15_1
  doi: 10.1212/WNL.0b013e3181d55f4d
– ident: e_1_2_15_25_1
  doi: 10.3109/13506129.2011.574354029
– ident: e_1_2_15_36_1
  doi: 10.1016/j.healun.2013.09.004
– ident: e_1_2_15_7_1
  doi: 10.1182/blood-2011-07-365510
– ident: e_1_2_15_99_1
  doi: 10.1371/journal.pone.0052686
– ident: e_1_2_15_70_1
  doi: 10.1182/blood-2004-08-3231
– ident: e_1_2_15_79_1
  doi: 10.1200/JCO.2010.30.5235
– ident: e_1_2_15_50_1
  doi: 10.1002/ajh.23827
– ident: e_1_2_15_23_1
  doi: 10.1093/qjmed/hcr105
– ident: e_1_2_15_33_1
  doi: 10.1038/bmt.2012.170
– ident: e_1_2_15_61_1
  doi: 10.1586/17474086.2014.858594
– ident: e_1_2_15_87_1
  doi: 10.1182/blood-2006-07-030544
– ident: e_1_2_15_92_1
  doi: 10.1053/j.ajkd.2008.05.022
– ident: e_1_2_15_42_1
  doi: 10.3324/haematol.11325
– ident: e_1_2_15_51_1
  doi: 10.1200/JCO.2011.38.5724
– ident: e_1_2_15_71_1
  doi: 10.1200/JCO.2011.37.7614
– ident: e_1_2_15_10_1
  doi: 10.1182/blood-2011-01-330738
– volume: 148
  start-page: 929
  year: 1988
  ident: e_1_2_15_27_1
  article-title: Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain)
  publication-title: Archives of Internal Medicine
  doi: 10.1001/archinte.1988.00380040169024
– ident: e_1_2_15_104_1
  doi: 10.1182/blood-2012-12-473066
– volume: 124
  start-page: 35
  year: 2014
  ident: e_1_2_15_46_1
  article-title: A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis
  publication-title: Blood
  doi: 10.1182/blood.V124.21.35.35
– ident: e_1_2_15_69_1
  doi: 10.1182/blood-2003-08-2788
– ident: e_1_2_15_45_1
  doi: 10.1182/blood-2011-12-396903
– ident: e_1_2_15_9_1
  doi: 10.3324/haematol.13369
– ident: e_1_2_15_96_1
  doi: 10.1182/blood-2011-10-388462
– ident: e_1_2_15_31_1
  doi: 10.3324/haematol.12982
– ident: e_1_2_15_81_1
  doi: 10.1056/NEJMoa1404852
– ident: e_1_2_15_53_1
  doi: 10.1038/leu.2012.274
– volume: 74
  start-page: 1108
  year: 1989
  ident: e_1_2_15_28_1
  article-title: The plasma cell labeling index: a valuable tool in primary systemic amyloidosis
  publication-title: Blood
  doi: 10.1182/blood.V74.3.1108.1108
– ident: e_1_2_15_41_1
  doi: 10.3324/haematol.2014.104109
– ident: e_1_2_15_30_1
  doi: 10.1002/ajh.20381
– ident: e_1_2_15_37_1
  doi: 10.15252/emmm.201404190
– ident: e_1_2_15_88_1
  doi: 10.1111/j.1600-6143.2010.03227.x
– ident: e_1_2_15_48_1
  doi: 10.1002/ajh.23936
– ident: e_1_2_15_95_1
  doi: 10.1038/ki.2014.122
– ident: e_1_2_15_106_1
  doi: 10.1111/bjh.13155
– ident: e_1_2_15_16_1
  doi: 10.3324/haematol.2013.084574
– volume: 124
  start-page: 3450
  year: 2014
  ident: e_1_2_15_62_1
  article-title: Long‐Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light‐Chain (AL) Amyloidosis (RRAL)
  publication-title: Blood
  doi: 10.1182/blood.V124.21.3450.3450
– volume: 124
  start-page: 3485
  year: 2014
  ident: e_1_2_15_105_1
  article-title: A matched case control study of doxycycline added to chemotherapy for reducing early mortality in patients with advanced cardiac AL amyloidosis from the alchemy study cohort
  publication-title: Blood
  doi: 10.1182/blood.V124.21.3485.3485
– ident: e_1_2_15_98_1
  doi: 10.1182/blood-2009-07-230722
– ident: e_1_2_15_55_1
  doi: 10.1111/jce.12123
– ident: e_1_2_15_24_1
  doi: 10.1182/blood-2014-11-609883
– ident: e_1_2_15_68_1
  doi: 10.1046/j.1460-9592.2001.01228.x
– ident: e_1_2_15_93_1
  doi: 10.1016/j.healun.2013.01.987
– ident: e_1_2_15_86_1
  doi: 10.1016/j.hoc.2014.08.013
– ident: e_1_2_15_13_1
  doi: 10.1056/NEJMoa065644
– ident: e_1_2_15_49_1
  doi: 10.1200/JCO.2013.50.8499
– ident: e_1_2_15_63_1
  doi: 10.1182/blood-2011-11-390930
– ident: e_1_2_15_57_1
  doi: 10.3109/13506129.2010.543443
– ident: e_1_2_15_38_1
  doi: 10.1056/NEJM199008233230803
– ident: e_1_2_15_83_1
  doi: 10.1182/blood-2011-02-334227
– ident: e_1_2_15_17_1
  doi: 10.1182/blood-2013-10-525634
– ident: e_1_2_15_65_1
  doi: 10.1152/ajpheart.00186.2013
– ident: e_1_2_15_78_1
  doi: 10.1182/blood-2011-05-355784
– ident: e_1_2_15_20_1
  doi: 10.1002/ajh.21822
– ident: e_1_2_15_26_1
  doi: 10.1016/0002-9343(88)90505-0
– ident: e_1_2_15_91_1
  doi: 10.1073/pnas.0912263107
– ident: e_1_2_15_21_1
  doi: 10.1182/blood-2012-02-413161
– ident: e_1_2_15_18_1
  doi: 10.1200/JCO.2004.03.029
– volume: 120
  start-page: 4057
  year: 2012
  ident: e_1_2_15_72_1
  article-title: Treatment of AL amyloidosis with bendamustine
  publication-title: Blood (ASH Annual Meeting Abstracts)
– ident: e_1_2_15_40_1
  doi: 10.1056/NEJMoa070484
– ident: e_1_2_15_84_1
  doi: 10.1056/NEJMoa1504942
– ident: e_1_2_15_85_1
  doi: 10.1161/01.CIR.63.6.1285
– ident: e_1_2_15_3_1
  doi: 10.1182/blood-2010-02-268987
– ident: e_1_2_15_11_1
  doi: 10.1111/bjh.13500
– ident: e_1_2_15_43_1
  doi: 10.1111/j.1365-2141.2010.08288.x
– ident: e_1_2_15_54_1
  doi: 10.1161/circ.104.14.1594
– ident: e_1_2_15_14_1
  doi: 10.1097/TP.0b013e3181f10edb
– ident: e_1_2_15_82_1
  doi: 10.1016/j.jcmg.2011.03.016
– ident: e_1_2_15_97_1
  doi: 10.1038/leu.2014.218
– ident: e_1_2_15_75_1
  doi: 10.1038/leu.2014.227
– ident: e_1_2_15_66_1
  doi: 10.2353/ajpath.2006.060183
– ident: e_1_2_15_101_1
  doi: 10.1182/blood-2011-04-351643
– ident: e_1_2_15_19_1
  doi: 10.1182/blood-2006-07-032987
– ident: e_1_2_15_44_1
  doi: 10.1200/JCO.2009.23.8220
– ident: e_1_2_15_94_1
  doi: 10.1093/ndt/gfs492
– ident: e_1_2_15_90_1
  doi: 10.1182/blood-2011-06-358507
– ident: e_1_2_15_29_1
  doi: 10.1038/sj.bmt.1704691
– ident: e_1_2_15_67_1
  doi: 10.1182/blood-2010-07-294405
– ident: e_1_2_15_60_1
  doi: 10.1056/NEJMra023144
– ident: e_1_2_15_47_1
  doi: 10.1038/bcj.2015.45
– ident: e_1_2_15_2_1
  doi: 10.1182/blood-2004-04-1424
– volume: 122
  start-page: 288
  year: 2013
  ident: e_1_2_15_64_1
  article-title: High‐dose pomalidomide and dexamethasone induce rapid responses in patients with AL amyloidosis exposed to alkylators, immune modulatory drugs, and proteasome inhibitors
  publication-title: Blood
  doi: 10.1182/blood.V122.21.288.288
SSID ssj0013051
Score 2.4625418
SecondaryResourceType review_article
Snippet Summary Immunoglobulin light chain (AL) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that...
Immunoglobulin light chain ( AL ) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive...
Immunoglobulin light chain (AL) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 170
SubjectTerms Amyloidosis - diagnosis
Amyloidosis - immunology
Amyloidosis - therapy
heart failure
Humans
Immunoglobulin Light Chains - metabolism
Immunoglobulin Light-chain Amyloidosis
immunoglobulins
light chains
mass spectrometry
Melphalan - therapeutic use
monoclonal antibodies
Myeloablative Agonists - therapeutic use
Plasma Cells - drug effects
Plasma Cells - pathology
Risk Assessment - methods
Stem Cell Transplantation - methods
Treatment Outcome
Title Recent advances in the management of AL Amyloidosis
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbjh.13805
https://www.ncbi.nlm.nih.gov/pubmed/26491974
https://www.proquest.com/docview/1760863444
Volume 172
WOSCitedRecordID wos000367900200004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Free Content
  customDbUrl:
  eissn: 1365-2141
  dateEnd: 20241209
  omitProxy: false
  ssIdentifier: ssj0013051
  issn: 0007-1048
  databaseCode: WIN
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
– providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1365-2141
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0013051
  issn: 0007-1048
  databaseCode: DRFUL
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwEB2VghAX9qUslUEcuAQ1iZPY4lSWqqBSIUSht8hLIopoipqW72eyQgVISJySgz2yZmzPe_Z4BuA4YGHDs0QS5-dog0otDSEa2uDS0gr9L1fpq_fHjtftsn6f31XgrHgLk-WHKA_ckpWR7tfJAhcy_rLI5cvzqWmzNH-pSc2kesHTdffzBqHh5NXyPNxqKMuzCiVRPGXPWV_0DWDO4tXU4bRW_jXUVVjOcSZpZhNjDSpBtA6Lt_lN-gbYiBfR35A8BiAmg4ggFiTDMhyGjELS7JDmECn9QI_iQbwJvdbVw0XbyAsoGAodr2MoJxBcMydQUiCD9kwaIgCRlDlauoKHWoQy4XsMv1QzFnIdaldyVyjTEpZjb0E1GkXBDhAEHiaT3HY8RGAoAXEVD1zEBwr5DpK2GpwUqvRVnl08KXLx6hcsA5Xgp0qowVHZ9C1LqfFTo8PCHj5O-OQWQ0TBaBr7puciDbMppTXYzgxVikF0x01kSDia1B6_y_fPb9rpz-7fm-7BEsKl_ABmH6qT8TQ4gAX1PhnE4zrMeX1Wh_nL-1avU08n4wdqRdxr
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1LT8JAEMcnBI168f3A52o8eKmhdNvuJl7QSECBeEDl1uyjjRhpDQU_v7OlVI2amHhqD9tNs6_5_XdnZwBOQxZV_Zowfn6utqjU0hKiqi0ua1qh_eUqu_X-0Pa7Xdbv87sSXMzuwkzjQxQbbmZmZOu1meBmQ_rTLJfPT-e2w0wA0zmKoGESNzy2uh9nCFU3z5fn42JDWR5XyPjxFJ9-tUbfEPMrsWYmp7Hyv59dheUcNUl9OjbWoBTG67DQyQ_TN8BBZESTQ3I3gJQMYoI4SIaFRwxJIlJvk_oQVf1AJ-kg3YT7xnXvqmnlORQshbbXtZQbCq6ZGyopUET7No2QQSRlrpae4JEWkTSSj-GTasYiriPtSe4JZddEzXW2oBwncbgDBNnDZpI7ro8QhjUgWvHQQ0RQKHlQt1XgbNaWgcoDjJs8Fy_BTGhgIwRZI1TgpCj6Oo2q8VOh41mHBDjmzUGGiMNkkga276EScyilFdie9lRRDQIet1Ek4d9kHfJ7_cHlTTN72f170SNYbPY67aDd6t7uwRLSU74fsw_l8WgSHsC8ehsP0tFhNhbfASRK3gE
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEB5KFfHi-1GfUTx4Wel2s7sJeKmP4qMWESvelrwWK7qVbvX3O9mmq6KC4Gn3kAxhJsl8XzKZAdgzLK3HDWHj_ELtUamlJ0Rde1w2tEL_y1Xx6v2uHXc67P6eX1fgcPwWZpQfojxwsyuj2K_tAjcvOv20yuXjw4EfMJvAdILaIjJVmDi5aXXbH7cI9dBVzItxu6HMZRaykTxl56_-6BvI_IpZC6fTmv3fcOdgxoFN0hzNjnmomGwBpq7cdfoiBAga0ekQFwiQk15GEBCS5zImhvRT0myT5jPy-p7u5718Cbqt09vjM89VUfAUet_QU6ERXLPQKCmQRsc-TRGFSMpCLSPBUy1SaUkfwy_VjKVcpzqSPBLKb4hGGCxDNetnZhUIog-fSR6EMcIwlIDgipsIQYJC0oPMrQb7Y10myqUYt5UunpIx1UAlJIUSarBbNn0Z5dX4qdHO2CAJznp7lSEy03_NEz-OkIsFlNIarIwsVYpBiMd9pEk4msIgv8tPji7Oip-1vzfdhqnrk1bSPu9crsM0wid3ILMB1eHg1WzCpHob9vLBlpuM73Pi3qo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+advances+in+the+management+of+AL+Amyloidosis&rft.jtitle=British+journal+of+haematology&rft.au=Kastritis%2C+Efstathios&rft.au=Dimopoulos%2C+Meletios+A.&rft.date=2016-01-01&rft.issn=0007-1048&rft.eissn=1365-2141&rft.volume=172&rft.issue=2&rft.spage=170&rft.epage=186&rft_id=info:doi/10.1111%2Fbjh.13805&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_bjh_13805
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1048&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1048&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1048&client=summon